These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14966076)

  • 1. Massive pulmonary haemorrhage complicating the treatment of acute coronary syndrome.
    Gill DS; Ng K; Ng KS
    Heart; 2004 Mar; 90(3):e15. PubMed ID: 14966076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty.
    Guo J; Xu M; Xi Y
    Tex Heart Inst J; 2012; 39(1):99-103. PubMed ID: 22412240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse alveolar hemorrhage following administration of tirofiban in a patient with acute coronary syndrome: a fatal complication.
    Yilmaz MB; Akin Y; Biyikoglu SF; Guray U; Korkmaz S
    Int J Cardiol; 2004 Jan; 93(1):81-2. PubMed ID: 14729442
    [No Abstract]   [Full Text] [Related]  

  • 5. Pulmonary hemorrhage in a patient with acute coronary syndrome.
    Fernández-Perez GC; Vázquez M; Delgado C; Velasco M; Vázquez-Lima A; Rodríguez-Pérez J
    AJR Am J Roentgenol; 2007 Sep; 189(3):W135-7. PubMed ID: 17715079
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
    Bakhai A; Flather MD; Collinson JR; Stevens W; Normand C; Alemao E; Itzler R; Ben-Joseph R
    Int J Cardiol; 2003 Oct; 91(2-3):163-72. PubMed ID: 14559126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tirofiban in acute coronary syndromes.
    Menozzi A; Merlini PA; Ardissino D
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):193-206. PubMed ID: 15853593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon CP; Weintraub WS; Demopoulos LA; Vicari R; Frey MJ; Lakkis N; Neumann FJ; Robertson DH; DeLucca PT; DiBattiste PM; Gibson CM; Braunwald E;
    N Engl J Med; 2001 Jun; 344(25):1879-87. PubMed ID: 11419424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
    Okmen E; Cakmak M; Tartan Z; Cam N
    Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
    Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor].
    Rasmussen S; Husted SE
    Ugeskr Laeger; 2001 Jan; 163(4):461-5. PubMed ID: 11218789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
    Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
    Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential benefits and outcomes of tirofiban vs abciximab for acute coronary syndromes in current clinical practice.
    Gowda MS; Vacek JL; Lakkireddy DJ; Brosnahan K; Beauchamp GD
    Angiology; 2003; 54(2):211-8. PubMed ID: 12678197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exit of platelet glycoprotein-IIb/IIIa-receptor inhibitors?
    Adam PC; Pemberton J; Evemy KL
    Lancet; 2001 May; 357(9267):1535-6. PubMed ID: 11386297
    [No Abstract]   [Full Text] [Related]  

  • 18. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirofiban in unstable coronary disease.
    Liron M
    N Engl J Med; 1998 Oct; 339(16):1163-5. PubMed ID: 9776651
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.